Biomarker Found for Celiac Patients on Gluten-Free Diet
|
By LabMedica International staff writers Posted on 19 Jun 2019 |
|
Representative histologic features of the small intestine. In the normal duodenal biopsy (A), the villi are elongated and the crypts relatively short. This is in contrast to the small intestinal tissue affected by celiac disease (B), which demonstrates marked villus blunting and crypt hyperplasia. (Photo courtesy of Tracy R. Ediger MD, and Ivor D. Hill, MD ChB).
Celiac disease is a complex condition, routinely treated by means of a strict gluten-free diet (GFD). One of the diagnostic challenges of this disease is that patients need to be consuming gluten so that a correct diagnosis by means of endoscopy can be made.
Celiac disease (CeD) is an immune-mediated enteropathy with a strong genetic component, where alleles encoding Human Leukocyte Antigen (HLA)-DQ2 and -DQ8 molecules account for 40% of disease heritability. A genetic, constitutive biomarker present also when the disease-triggering insult is absent would be extremely useful for the diagnosis this conditions.
Scientists associated with the University of the Basque Country (Leioa, Spain) hypothesized that merging different levels of genomic information through Mendelian Randomization (MR) could help discover genetic biomarkers useful for CeD diagnosis. MR was performed using public databases (9,451 cases and 16,434 controls) of expression quantitative trait loci (eQTL) and methylation QTL (mQTL) as exposures, and the largest CeD genome-wide association study (GWAS) conducted to date as the outcome, in order to identify potential causal genes.
The scientists identified UBE2L3, an ubiquitin ligase located in a CeD-associated region. They interrogated the expression of UBE2L3 in an independent dataset of peripheral blood mononuclear cells (PBMCs) and found that its expression is altered in CeD patients on GFD when compared to non-celiac controls. The relative expression of UBE2L3 isoforms predicts CeD with 100% specificity and sensitivity and could be used as a diagnostic marker, especially in the absence of gluten consumption.
The authors concluded that the relative expression of the isoforms of the UBE2L3 gene in the blood makes it possible to distinguish with 100% sensitivity and specificity celiac patients on a gluten-free diet. The approach used could be applicable to other diseases where diagnosis of asymptomatic patients can be complicated. The study was published on May 29, 2019, in the journal Human Molecular Genetics.
Related Links:
University of the Basque Country
Celiac disease (CeD) is an immune-mediated enteropathy with a strong genetic component, where alleles encoding Human Leukocyte Antigen (HLA)-DQ2 and -DQ8 molecules account for 40% of disease heritability. A genetic, constitutive biomarker present also when the disease-triggering insult is absent would be extremely useful for the diagnosis this conditions.
Scientists associated with the University of the Basque Country (Leioa, Spain) hypothesized that merging different levels of genomic information through Mendelian Randomization (MR) could help discover genetic biomarkers useful for CeD diagnosis. MR was performed using public databases (9,451 cases and 16,434 controls) of expression quantitative trait loci (eQTL) and methylation QTL (mQTL) as exposures, and the largest CeD genome-wide association study (GWAS) conducted to date as the outcome, in order to identify potential causal genes.
The scientists identified UBE2L3, an ubiquitin ligase located in a CeD-associated region. They interrogated the expression of UBE2L3 in an independent dataset of peripheral blood mononuclear cells (PBMCs) and found that its expression is altered in CeD patients on GFD when compared to non-celiac controls. The relative expression of UBE2L3 isoforms predicts CeD with 100% specificity and sensitivity and could be used as a diagnostic marker, especially in the absence of gluten consumption.
The authors concluded that the relative expression of the isoforms of the UBE2L3 gene in the blood makes it possible to distinguish with 100% sensitivity and specificity celiac patients on a gluten-free diet. The approach used could be applicable to other diseases where diagnosis of asymptomatic patients can be complicated. The study was published on May 29, 2019, in the journal Human Molecular Genetics.
Related Links:
University of the Basque Country
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Gold Member
Platelet Function Analyzer
AGGRENG-40
Electrolyte Analyzer
BKE-B
Latest Molecular Diagnostics News
- Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer
- Genomic Breast Cancer Study Adds Real-World Evidence Across Diverse Patient Populations
- CSF Liquid Biopsy Could Help Distinguish Cancer from Autoimmune Brain Inflammation
- Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis
- Computational Filters Enhance Metagenomic Detection of Meningitis and Encephalitis
- Mpox Analysis Reveals Substantial Suspected False Positives Associated with Contamination
- Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors
- Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery
- Electronic Genome Mapping Reveals Structural Abnormalities in Hematologic Malignancies
- Rare Genetic Variant Linked to Dramatically Higher Lung Cancer Risk
- Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer
- Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples
- FDA Clears Compact Molecular COVID Test for Decentralized Care Settings
- Blood-Based DNA Analysis Method Detects Early-Stage Solid Cancers
- Combined Blood and Genetic Tests Estimate Timing of Alzheimer’s Symptom Onset
- Blood Protein Analysis Helps Interpret Uncertain Rare Disease Variants
Channels
Clinical Chemistry
view channel
Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more
First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more
Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options
Many lethal cancers lack routine screening and are often diagnosed only after symptoms emerge, limiting curative options. Standard programs in the United States cover a small subset of malignancies, leaving... Read more
Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes
Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent
Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more
Blood Biomarker May Predict Colitis Risk in Checkpoint Inhibitor Therapy
Immune checkpoint inhibitors can trigger immune-related colitis that leads to severe diarrhea, abdominal pain, and treatment interruptions. Clinicians currently lack validated tools to identify which patients... Read more
Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more
Microbiology
view channel
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more
Pathology
view channel
Simple Test Could Reduce the Need for Invasive Uterine Cancer Checks
Bleeding after menopause requires prompt investigation for uterine cancer, although most women who undergo testing do not have the disease. In the U.K., uterine cancer affects nearly 10,000 women each... Read more
Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival
Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more
Multimodal AI Improves Breast Cancer Recurrence Risk Prediction Beyond Standard Genomic Testing
Predicting which patients with early-stage breast cancer will develop distant recurrence remains difficult, complicating decisions about long-term therapy and surveillance. Widely used genomic assays are... Read more
Technology
view channel
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more
Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read moreIndustry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more
